Wave Life Sciences Ltd.
NASDAQWVE enters the week after a Q1 results print with an unusual split: short sellers are rapidly unwinding positions while the Street scrambles to revise down price targets — a collision between two groups moving in opposite directions. The most striking development in positioning is the speed of short covering. Short interest fell 27% in a single week to 9.4% of the free float…
WVE short interest fell 26.7% over the past week to 9.4% of float, as short sellers unwound positions amid clinical-stage biotech volatility. Cost to borrow remains benign at 0.50%, with massive availability at 1,236% of short interest.
WVE enters the week after a Q1 results print with an unusual split: short sellers are rapidly unwinding positions while the Street scrambles to revise down price targets — a collision between two groups moving in…
Wave Life Sciences heads into the final stretch before its mid-2026 FDA accelerated approval decision with short interest climbing, analyst targets sitting far above the current price, and options traders tilting…
Snapshot as of 6 Aug 2026
Wave Life Sciences exits its May earnings week battered — down 10% in a single session and nearly 10% on the week — with analysts racing to reprice a stock that has lost more than half its value this year. The…
Wave Life Sciences presents a rare split-signal setup. Short sellers are building positions hard. Options traders are piling into calls. Analysts keep Buy ratings but are slashing targets. All three moved sharply in…
Wave Life Sciences heads into its May 8 earnings with one dominant story: a $55 million insider buying cluster that now looks increasingly misaligned with where the stock and analyst targets sit. The most compelling…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for WVE — free to start on ORTEX.
Sign up for free →Open WVE on ORTEX